Boehringer Ingelheim

INGELHEIM, GermanyPharmaceutical3 H-1B visas (FY2023)

Focus: Boehringer Ingelheim is a global pharmaceutical company with 53,000 employees headquartered in Germany, competing as a major player in small molecules and biologics across respiratory, oncology, cardiovascular, immunology, and neuroscience.

Respiratory Oncology Cardiovascular Immunology

Profile data last refreshed 6h ago · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Employees

53,000

Open Jobs

About Boehringer Ingelheim

AI assessmentNot Hiring

No open roles listed right now. Follow Boehringer Ingelheim to get notified when they start hiring — the background below is worth knowing for when they do.

Generated by Claude from Boehringer Ingelheim's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Data completeness

5/9 — Partial

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

STRIVERDI RESPIMAT

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

JARDIANCE

Sodium-Glucose Cotransporter 2 Inhibitor

$8.8B Part D

Peak8.2yr

Help build intelligence for Boehringer Ingelheim

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact

Parkinson Disease

N/A

Clinical Trials (1)

NCT01100073Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life

N/A

Pramipexole

Restless Legs Syndrome

N/A

Clinical Trials (1)

NCT02248155Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

N/A

Pramipexole

Parkinson Disease

N/A

Clinical Trials (1)

NCT02236728Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

N/A

Pramipexole immediate release

Parkinson Disease

N/A

Clinical Trials (1)

NCT00651183Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

N/A

Pramipexole

Parkinson Disease

N/A

Clinical Trials (1)

NCT02248220Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

N/A

Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINIO

Parkinson Disease

N/A

Clinical Trials (1)

NCT00617019Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)

N/A

Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's

Parkinson Disease

N/A

Clinical Trials (1)

NCT00539214Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease

N/A

Pramipexole

Parkinson Disease

N/A

Clinical Trials (1)

NCT02248168Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

N/A

Pramipexole Extended Release

Parkinson Disease

N/A

Clinical Trials (1)

NCT01097421Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

N/A

Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restle

Restless Legs Syndrome

N/A

Clinical Trials (1)

NCT00887289Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)

N/A

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

Parkinson Disease

N/A

Clinical Trials (1)

NCT00615914Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

N/A

Pramipexole

Parkinson Disease

N/A

Clinical Trials (1)

NCT02248207Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

N/A

Pramipexole

Restless Legs Syndrome

N/A

Clinical Trials (1)

NCT02248142Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

N/A

pramipexole

Parkinson Disease

N/A

Clinical Trials (1)

NCT01361009a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

N/A

Pramipexole

Parkinson Disease

N/A

Clinical Trials (1)

NCT00349310Profile of Depressive Symptoms in Parkinsons Disease

N/A

expert support for interpretation of spirometry

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT00131157Evaluation of Spirometry Expert Support in General Practice

N/A

ARB

Neoplasm

N/A

Clinical Trials (4)

NCT07472517DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Phase 3

NCT07544654DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Integrative-omics of the Disordered COPD Small Airway Epithelium

Smoking

N/A

Clinical Trials (1)

NCT02183818Integrative-omics of the Disordered COPD Small Airway Epithelium

N/A

Experimental

Impulse Control Disorders

N/A

Clinical Trials (1)

NCT02755181fMRI in Impulsivity

N/A

A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT04097223A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)

N/A

GIOTRIF 20mg

Carcinoma, Non-Small-Cell Lung

N/A

Clinical Trials (1)

NCT02285361GIOTRIF rPMS in Korean Patients With NSCLC

N/A

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progress

Rheumatoid Lung

N/A

Physical Training

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT05140226Cognitive and Physical Training in Patients With Chronic Obstructive Pulmonary Disease Patients

N/A

Berodual® Respimat® solution for inhalation

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02231372Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

N/A

Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation

Auricular Fibrillation

N/A

Clinical Trials (1)

NCT04133545Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation

N/A

Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COP

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02719184Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)

N/A

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung

Carcinoma, Non-Small-Cell Lung

N/A

Clinical Trials (1)

NCT02381808Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

N/A

mgt of bleeding concerns/complications of oral anticoagulants

Blood Coagulation

N/A

The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With

Pulmonary Fibrosis

N/A

Clinical Trials (1)

NCT06912659The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib

N/A

Multiple-Breath-Washout

Pulmonary Fibrosis

N/A

Clinical Trials (1)

NCT06179342Multiple Breath Washout as a Method for Diagnosing Lung Diseases

N/A

Vahelva® Respimat®

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02864407Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

N/A

Tamsulosin

Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT02245503Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

N/A

SATisfaction and Adherence to COPD Treatment

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02689492SATisfaction and Adherence to COPD Treatment

N/A

Gladem

Depressive Disorder

N/A

Clinical Trials (1)

NCT02231268Observational Study to Assess a 6-months Treatment With Gladem

N/A

inhaled bronchodilator

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02176564Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease

N/A

Tamsulosin

Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT02244320Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

N/A

Berodual® Respimat® solution for inhalation

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02231359Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

N/A

population-based screening for chronic kidney disease

Kidney Disease, Chronic

N/A

Clinical Trials (1)

NCT06223750Virtual Kidney Check and Follow-up

N/A

Intervention Group

Heart Diseases

N/A

Clinical Trials (1)

NCT00985179Increasing Vitamin Intake and Physical Activity

N/A

SMS reminder

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT01308476SMS Reminder to Assess Adherence

N/A

Education

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT00268866Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung Clinics

N/A

OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02719639OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)

N/A

Tamsulosin

Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT02245555Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

N/A

Lendormin D tablets

Sleep Initiation and Maintenance Disorders

N/A

Clinical Trials (1)

NCT02224014Lendormin D® Tablet (Drug Use Result Survey)

N/A

ALNA®

Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT02244333Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

HIV Infections

N/A

Digital Behaviour Change Intervention

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT04085302TARA Working Prototype Engagement Evaluation: Feasibility Study

N/A

Pulmonary function test

Connective Tissue Diseases

N/A

Clinical Trials (1)

NCT04095351Connective Tissue Diseases and Lung Manifestations

N/A

Olodaterol

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT03030638Drug Utilization Study for Olodaterol

N/A

Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT04320524TARA Working Prototype [Version 2]: Feasibility Study

N/A

12.1 Mechanism of Action Tipranavir is an antiretroviral drug [ see ]. 12.2 Pharmacodynamics ECG Evaluation The effect of APTIVUS/ritonavir on the QTcF interval was measured in a study in which 81 healthy subjects received the following treatments twice daily for 2.5 days: APTIVUS/ritonavir (500 mg/200 mg), APTIVUS/ritonavir at a supra-therapeutic dose (750 mg/200 mg), and placebo/ritonavir (-/200 mg). After baseline and placebo adjustment, the maximum mean QTcF change was 3.2 ms (1-sided 95% Upper CI: 5.6 ms) for the 500 mg/200 mg dose and 8.3 ms (1-sided 95% Upper CI: 10.9 ms) for the supra-therapeutic 750 mg/200 mg dose. Antiviral Activity in vivo The median Inhibitory Quotient (IQ) determined from 264 treatment-experienced adult subjects was about 80 (inter-quartile range: 31-226), from the controlled clinical trials 1182.12 and 1182.48. The IQ is defined as the tipranavir trough concentration divided by the viral EC 50 value, corrected for protein binding. There was a relationship between the proportion of subjects with a ≥1 log 10 reduction of viral load from baseline at week 48 and their IQ value. Among the 198 subjects receiving APTIVUS/ritonavir with no new enfuvirtide use (e.g., new enfuvirtide, defined as initiation of enfuvirtide for the first time), the response rate was 23% in those with an IQ value <80 and 59% in those with an IQ value ≥80. Among the 66 subjects receiving APTIVUS/ritonavir with new enfuvirtide, the response rates in subjects with an IQ value <80 versus those with an IQ value ≥80 were 55% and 71%, respectively. These IQ groups are derived from a select population and are not meant to represent clinical breakpoints. 12.3 Pharmacokinetics In order to achieve effective tipranavir plasma concentrations and a twice-daily dosing regimen, co-administration of APTIVUS with ritonavir is essential [ see ]. Ritonavir inhibits hepatic cytochrome P450 3A (CYP3A), the intestinal P-gp efflux pump and possibly intestinal CYP3A. In a dose-ranging evaluation in 113 HIV-1 negative male and female volunteers, there was a 29-fold increase in the geometric mean morning steady-state trough plasma concentrations of tipranavir following APTIVUS co-administered with low-dose ritonavir (500 mg/200 mg twice daily) compared to APTIVUS 500 mg twice daily without ritonavir. In adults the mean systemic ritonavir concentration when 200 mg of ritonavir was given with 500 mg of APTIVUS was similar to the concentrations observed when 100 mg was given with the other protease inhibitors. Figure 1 displays mean plasma concentrations of tipranavir and ritonavir at steady state for 30 HIV-1 infected adult subjects dosed with 500 mg/200 mg tipranavir/ritonavir for 14 days. Figure 1 Mean Steady State Tipranavir Plasma Concentrations (95% CI) with Ritonavir Co-administration (tipranavir/ritonavir 500 mg/200 mg BID) Figure 1 Absorption and Bioavailability Absorption of tipranavir in humans is limited, although no absolute quantification of absorption is available. Tipranavir is a P-gp substrate, a weak P-gp inhibitor, and appears to be a potent P-gp inducer as well. In vivo data suggest that tipranavir/ritonavir, at the dose of 500 mg/200 mg, is a P-gp inhibitor after the first dose and induction of P-gp occurs over time. Tipranavir trough concentrations at steady-state are about 70% lower than those on Day 1, presumably due to intestinal P-gp induction. Steady state is attained in most subjects after 7-10 days of dosing. Dosing APTIVUS 500 mg with 200 mg ritonavir capsules twice daily for greater than 2 weeks and without meal restriction produced the pharmacokinetic parameters for male and female HIV-1 positive subjects presented in Table 5. Table 5 Pharmacokinetic Parameters of tipranavir/ritonavir 500 mg/200 mg for HIV-1 Positive Subjects by Gender Parameter Females (n=14) Males (n=106) Population pharmacokinetic parameters reported as mean ± standard deviation Cp trough (µM) 41.6 ± 24.3 35.6 ± 16.7 C max (µM) 94.8 ± 22.8 77.6 ± 16.6 T max (h) 2.9 3.0 AUC 0-12h (µM∙h) 851 ± 309 710 ± 207 CL (L/h) 1.15 1.27 V (L) 7.7 10.2 t 1/2 (h) 5.5 6.0 Effects of Food on Oral Absorption For APTIVUS capsules co-administered with ritonavir capsules at steady-state, no clinically significant changes in tipranavir C max , Cp12h, and AUC were observed under fed conditions (500-682 Kcal, 23-25% calories from fat) compared to fasted conditions [ see ]. The effect of food on tipranavir exposure when APTIVUS capsules is co-administered with ritonavir tablets has not been evaluated [ see ]. For information on the effect of food on the bioavailability of ritonavir tablets, please refer to the ritonavir tablet prescribing information. Distribution Tipranavir is extensively bound to plasma proteins (>99.9%). It binds to both human serum albumin and α-1-acid glycoprotein. The mean fraction of tipranavir (dosed without ritonavir) unbound in plasma was similar in clinical samples from healthy volunteers and HIV-1 positive subjects. Total plasma ti

Boehringer Ingelheim

About Boehringer Ingelheim

Key Products

Products & Portfolio (27)

Key Products by Revenue

Other Products (8)

Pipeline & Clinical Trials

Recent News · Boehringer Ingelheim(10)

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)